New cancer clinical trial: Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Published on: March 29, 2018 at 12:00PM
Conditions:   Prostatic Neoplasms;   Prostatic Cancer
Interventions:   Biological: ETBX-071; adenoviral PSA vaccine;   Biological: ETBX-061; adenoviral MUC1 vaccine;   Biological: ETBX-051; adenoviral brachyury vaccine
Sponsor:   National Cancer Institute (NCI)
Recruiting
https://ift.tt/2JcyETg